Latest Generation VELscope Device Cleared for Sale in the U.S.

VELscope Vx System a Powerful Tool in the Fight Against Oral Disease and Oral Cancer

BURNABY, British Columbia—November 22, 2010—LED Dental Inc. announced today that its
VELscope Vx Enhanced Oral Assessment system has received 510(k) clearance from the U.S. Food
and Drug Administration (FDA) and is therefore now available for sale in the U.S. The VELscope Vx
system’s updated optics technology, unique cordless design and affordable pricing make it easier
than ever for dental practices to detect oral cancer and other forms of oral disease.
The first-generation VELscope device was introduced in 2006 and, since then, LED Dental has sold
almost 6,000 devices, which have been used to conduct almost 10 million enhanced oral soft tissue
exams worldwide. Oral soft tissue exams not only help detect all types of oral disease but are also
a key element of an oral cancer screening protocol. Today, VELscope fluorescence visualization
technology is used to conduct more enhanced oral exams than any other detection technology in
the world.
“We are extremely excited about the potential of the VELscope Vx system to significantly increase the number of dental practices conducting comprehensive screenings for oral cancer and other forms of oral disease,” said Peter Whitehead, founder and CEO of LED Dental. “The device’s portability makes it easy to transport between operatories within the dental practice, and its attractive pricing makes it possible for practices to charge very low exam fees to their patients.” Oral cancer kills one American every hour of every day. According to the SEER database, oral
cancer has a higher mortality rate than several better-publicized cancers, such as cervical cancer and testicular cancer. Some oral cancers are now known to be linked to exposure to the sexuallytransmitted
human papilloma virus (HPV), which means that anyone who is sexually active is potentially at risk for the disease. Because of this, many health experts advise everyone 18-yearsold and older to get an oral cancer exam on at least an annual basis.
Regular exams can help address the fact that oral cancer is typically discovered in late stages, when the 5-year survival rate is around 30%. When discovered in early stages, however, the survival rate leaps to 80-to-90%, according to SEER data. Early detection can help reduce not only the mortality rate, but the degree of invasiveness and disfigurement resulting from treatment.
The VELscope Vx shines a safe, blue light into the oral cavity and excites natural tissue fluorescence. When viewed by the clinician through the Vx’s patented filters, abnormal tissue typically appears as an irregular, dark area that stands out against the otherwise normal, green fluorescence pattern of surrounding healthy tissue.
VELscope Vx exams can help dental practices detect not only oral cancer, but other more common types of oral disease, such as viral, bacterial or fungal infections. Exams take only a few minutes, and are completely free of any pain or inconvenience for patients. To learn more about the VELscope Vx, or to find dental practices that offer VELscope exams, visit

About LED Dental
LED Dental Inc. is a wholly-owned subsidiary of LED Medical Diagnostics Inc., which was founded in
2003 and is headquartered in Burnaby, British Columbia, Canada. For more information, call +1
(604) 434-4614, or visit 2 LED Medical Diagnostics Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking
statements. Certain information included in this press release (as well as information included in
oral statements or other written statements made or to be made by the company) contains
statements that are forward-looking, such as statements relating to anticipated future revenues of
the company and success of current product offerings. Such forward-looking information involves
important risks and uncertainties that could significantly affect anticipated results in the future and,
accordingly, such results may differ materially from those expressed in any forward-looking
statements made by or on behalf of the company. For a description of additional risks and
uncertainties, please refer to the company’s filings with the Securities and Exchange Commission.